ResistanceBio is a target and drug discovery platform company focused on identifying novel therapies that overcome treatment-resistant cancer and enable personalized precision medicine. Platform: We’ve developed an in vitro and ex vivo cancer evolution model (the ResCu system®) that maps the cancer resistome by mimicking natural tumor response to treatment. ResCu and patient data combine to create our cancer resistome database. ResCu allows us to exploit novel cancer and immuno-oncology targets through deep learning and biological validation for better therapeutic outcomes for patients.
Natera in cell-free DNA testing. The mission of the company is to change the management of disease worldwide with a focus on women’s health, oncology, and organ health. Natera operates an ISO13485- certified and CAPaccredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, California. It offers proprietary genetic testing services to inform obstetricians, transplant physicians, oncologists, and cancer researchers, including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform.
Biodesix® is an experienced partner in the field of blood-based molecular diagnostic testing. Our comprehensive diagnostic testing capabilities help our partners decipher the complexity of cancer by interpreting genomic and proteomic information from both tumor biology and the patient’s immune response. Biodesix enables our partners throughout the discovery, development and commercialization of personalized diagnostics to support new therapies with companion diagnostic strategies.
As an expert in immune biomarkers, Veracyte’s goal is to play a leading role in partnering with the academic and pharmaceutical industry to leverage the immune contexture concept and deliver practical routine diagnostic tools to significantly impact therapy prescription for the benefit of patients. By precisely measuring the immune reaction in and around the tumor, Veracyte helps clinicians to determine the degree of severity of a patient’s disease and predict the response to treatment, regardless of the cancer stage or the molecular class.
We are a competitive and research intelligence database solution designed in partnership with pharmaceutical professionals across the world. We work in targeted therapies such as targeted protein degradation to provide accurate, in-depth, and real-time information in the rapidly evolving landscape of drug development.
Find out how we can accelerate your drug development program by visiting our website.